NASDAQ:AMRS - Amyris Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.44 -0.15 (-4.18 %)
(As of 01/23/2019 06:25 AM ET)
Previous Close$3.59
Today's Range$3.4050 - $3.59
52-Week Range$2.92 - $9.28
Volume632,716 shs
Average Volume812,840 shs
Market Capitalization$263.26 million
P/E Ratio-1.13
Dividend YieldN/A
Beta0.38
Amyris, Inc., an integrated renewable products company, engages in the research, development, and production of ingredients for the health and wellness, clean beauty, and flavors and fragrances markets worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company delivers its products and services under the No Compromise name across various markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. It has a collaboration agreement with Yifan Pharmaceutical Co., Ltd. and Givaudan SA. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryOil & Gas Refining & Marketing
SectorBasic Materials
Current SymbolNASDAQ:AMRS
CUSIP03236M10
Phone510-450-0761

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$143.45 million
Book Value($4.64) per share

Profitability

Net Income$-72,320,000.00
Net Margins-114.09%

Miscellaneous

Employees414
Market Cap$263.26 million
OptionableOptionable

Amyris (NASDAQ:AMRS) Frequently Asked Questions

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

When did Amyris' stock split? How did Amyris' stock split work?

Shares of Amyris reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

How were Amyris' earnings last quarter?

Amyris Inc (NASDAQ:AMRS) released its quarterly earnings data on Tuesday, November, 13th. The biotechnology company reported ($1.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.96. The biotechnology company earned $14.90 million during the quarter, compared to analyst estimates of $46.72 million. The business's revenue was down 38.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.81) EPS. View Amyris' Earnings History.

When is Amyris' next earnings date?

Amyris is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Amyris.

What price target have analysts set for AMRS?

2 equities research analysts have issued 12-month target prices for Amyris' stock. Their forecasts range from $8.00 to $11.00. On average, they expect Amyris' stock price to reach $9.50 in the next year. This suggests a possible upside of 176.2% from the stock's current price. View Analyst Price Targets for Amyris.

What is the consensus analysts' recommendation for Amyris?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amyris.

What are Wall Street analysts saying about Amyris stock?

Here are some recent quotes from research analysts about Amyris stock:
  • 1. According to Zacks Investment Research, "Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. " (1/15/2019)
  • 2. HC Wainwright analysts commented, "We believe the company is capitalizing on its relationship with Xinfu / Yifan to monetize a portion of the long-term royalty opportunity upfront, which should lower quarterly volatility from this high-margin revenue stream while continuing to benefit from future royalty payments." (12/31/2018)

Has Amyris been receiving favorable news coverage?

News headlines about AMRS stock have trended positive recently, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Amyris earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near future.

Who are some of Amyris' key competitors?

Who are Amyris' key executives?

Amyris' management team includes the folowing people:
  • Mr. John G. Melo, Pres, CEO & Director (Age 53)
  • Ms. Kathleen Valiasek, Chief Financial Officer (Age 55)
  • Mr. Eduardo Alvarez, Chief Operating Officer (Age 55)
  • Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 52)
  • Dr. Joel R. Cherry, Pres of R&D (Age 58)

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $3.44.

How big of a company is Amyris?

Amyris has a market capitalization of $263.26 million and generates $143.45 million in revenue each year. The biotechnology company earns $-72,320,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis. Amyris employs 414 workers across the globe.

What is Amyris' official website?

The official website for Amyris is http://www.amyris.com.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]


MarketBeat Community Rating for Amyris (NASDAQ AMRS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  237 (Vote Outperform)
Underperform Votes:  314 (Vote Underperform)
Total Votes:  551
MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote "Outperform" if you believe AMRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by MarketBeat.com Staff

Featured Article: Outstanding Shares

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel